**Figure 3.**

diagnostics of community to supervise infectious disease condition, vaccine effectiveness, immune defense perseverance, and high-titer neutralizing antibody monitoring and selection. These diagnostics, including the enzyme-linked immunochromatographic analysis (ELISA), chemiluminescent immunoassay (CLIA), immunofluorescent test (IFA), and colloidal gold immune chromatographic test (GICA), are lying on the detection of SARS-CoV-2 via IgM and/or IgG antibodies in blood plasma or biological fluids specimen. Several months before the first case was identified, one study looked for SARS-CoV-2 special antibody in 959 patients taken acquired from a prospective lung cancerous tumor testing between healthy people [44]. According to tests, SARS-CoV-2 disorders were found in about 11.6% of a native community before COVID-19 was discovered. Antibody tests are useful in community exposure research to determine the speed of exposure during a special pandemic episode in an area, as well as to determine regardless of where neutraliziable antibodies are progressing in people who were attacked by the COVID-19 virus, as well as the period and titer modified into neutralizing antibodies with the time. Since many types of vaccinations preventing SARS-CoV-2 disease are provided to the public, it is crucial to monitor neutralizing antibody production after immunization.
